Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populations. "We founded .
Moderna Launches New Charitable Foundation pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 / Moderna
Share this article
Share this article
NEW YORK and PERTH, Australia, March 17, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Michael Rosenblatt, MD, to its Board of Directors. Dr. Rosenblatt is a Senior Partner at Flagship Pioneering, a leading-edge innovation organization that conceives, creates and develops first-in-category life science companies, and the former Chief Medical Officer of Merck, one of the world s leading global biopharmaceutical companies.
Dr. Rosenblatt brings over four decades of visionary leadership experience across biopharmaceutical companies and academic institutions, and as a practicing physician. In his current role at Flagship, he has helped launch several renowned biotechnology companies in the Flagship ecosystem, including providing counsel on clinical development strategies a
Special: Moderna s CEO writes on the Covid-19 vaccine
Stéphane Bancel/Dubai
Photo:AFP
It took the power of science, human ingenuity and relentless determination to get here, Stéphane Bancel says
Since early January, we have chased this virus with the intent to protect as many people around the world as possible. We always worried about the fall/winter second wave given it is a respiratory virus. All along, we have known that each day matters.
It took the power of science, human ingenuity and relentless determination to get here.
Moderna’s journey started 10 years ago with a revolutionary, but unproven, concept that messenger RNA, mRNA, might become the basis for a transformative approach to developing medicines. Prior to our development of the Moderna Covid-19 Vaccine, we had enrolled more than 2,000 healthy volunteers across nine clinical trials for mRNA vaccines, including four first-in-class vaccine candidates, since entering the clinic in December 2015.